TPBG and ovarian cancer: Another protein, 5T4, an oncofetal TAA highly expressed in ovarian cancer [210], is also an attractive target for CAR-T cell therapy: co-culturing CAR-T cells, engineered from patient-derived T cells to target the 5T4 antigen, with autologous 5T4 + tumor cells often results in increased secretion of pro-inflammatory cytokines such as IFN-γ and IL-2.